Commission Decision 2003/896/EC of 19 December 2003 allowing Member States to extend provisional authorisations granted for the new active substances thiacloprid, thiametoxam, quinoxyfen, flazasulfuron, Spodoptera exigua nuclear polyhedrosis virus, spinosad, Giocladium catenulatum, Pseudomonas chlororaphis and indoxacarb
Procedure: See legal status below
Legal status
Adopted EU legal act marked as EEA relevant by the EU but considered by the EEA EFTA States not to be relevant for incorporation into the EEA Agreement. There may be a number of reasons for this: the act may fall outside the scope of the EEA Agreement; it may have expired in the EU; or incorporation may not be required due to the contents or nature of the act. For some of the acts, discussions with the EU on their relevance are still ongoing.
Area (EEA Agreement)
II Technical Regulations, Standards, Testing and Certification
II.XV Dangerous Substances
Legal Documents
Commission Decision 2003/896/EC of 19 December 2003 allowing Member States to extend provisional authorisations granted for the new active substances thiacloprid, thiametoxam, quinoxyfen, flazasulfuron, Spodoptera exigua nuclear polyhedrosis virus, spinosad, Giocladium catenulatum, Pseudomonas chlororaphis and indoxacarb
Entscheidung der Kommission vom 19. Dezember 2003 zur Ermächtigung der Mitgliedstaaten, die vorläufigen Zulassungen für die neuen Wirkstoffe Thiacloprid, Thiamethoxam, Quinoxyfen, Flazasulfuron, Spodoptera exigua Kernpolyedervirus, Spinosad, Giocladium catenulatum, Pseudomonas chlororaphis und Indoxacarb zu verlängern (2003/896/EG)
History
Disclaimer: EEA-Lex is provided for information purposes only. The information is not guaranteed or promised to be current or complete and is not intended to replace any applicable legal sources.